Sponsored by Epstein Becker & Green, P.C.

MedTech Metro is an intimate forum and networking series designed to showcase New York's bio/med technology before an audience of investors, business leaders and health care providers. This 2014 series will feature three companies seeking investment or partners and a keynote speaker at each event. MedTech is the hub of New York State's bioscience and medical technology industry. It is an active association of nearly 100 pharmaceutical, biotech and medical technology companies, their suppliers and service providers and research universities.


City of New York Early-Stage Life Sciences Funding Initiative, Eric J. Gertler, Executive Vice President and Managing Director, New York City Economic Development Corporation (NYCEDC)

Eric will be discussing the City of New York's Early-Stage Life Sciences Funding Initiative, which represents an unprecedented public-private partnership across world-class academic institutions, industry leaders, top-tier investors, and the philanthropic community. Established by the NYCEDC with at least $50 million in matching funds from top-tier venture capital partners including Celgene Corporation, GE Ventures, and Eli Lilly & Company, the funding partnership will deploy a minimum of $100 million and seeks to launch 15 to 20 breakthrough ventures by 2020.

Presenting Companies:

  • Thermal Gradient is a Rochester-based biotechnology company with proprietary technology that enables extremely rapid nucleic acid (DNA/RNA) testing. Through strategic partnerships and its own branded products, Thermal Gradient microfluidic devices, subsystems, and systems result in faster, smaller and less complex molecular diagnostic systems for use in health care, biodefense, biomedical research, environmental safety and other related fields. The company's present focus is in systems for infectious disease detection and therapeutic monitoring and on actively pursuing strategic alliances for other applications.
  • iFyber is a specialty materials company with corporate offices and laboratories located in Ithaca, New York. The company has experience in the commercial advancement of new technologies that require modulating the interfacial chemistry of a variety of substrates that include textiles, implantable medical devices, microspheres, and porous membranes. iFyber's development capabilities have expanded to include specialty chemicals for topical wound care treatments. These capabilities are specifically being applied to the advancement of nitric oxide delivery for chronic wounds through the advancement of topical formulations and fiber based dressings. iFyber has further applied its materials development expertise to a novel hemostatic agent for the wound care market. The hemostatic agent development relies on the company's capabilities related to new polymer synthesis, compound formulation, and experimental/regulatory guided testing.
  • Raland Therapeutics Inc. is a development stage company focused on biosensor systems for life sciences. Raland's proprietary technology is showcased in the CytoCommT Living Biosensor System, a real time monitoring system for biological signaling and cellular responses in oncology and other applications. The system transmits live data through the cloud to Raland's data acquisition and analysis software. Using this system, real time results are available to caregivers or researchers at their desk or in remote locations.


5:00-5:45 p.m. Registration / Cocktail and networking reception
5:45-6:00 p.m. Introduction by Jessica Crawford, President, MedTech Association
6:00-6:45 p.m. Presentations by:
Robert D. Juncosa, CEO, Thermal Gradient;
Eric Eisenhut, President, iFyber, LLC
Bill Rader, President and CEO, Raland Therapeutics Inc.
6:45-7:00 p.m. Introduction by:
Kamesh Nagarajan, Senior Vice President - Wealth Mgmt Senior Portfolio Manager, and International Client Advisor (ICA), Morgan Stanley
7:00-7:30 p.m. Eric J. Gertler, Executive Vice President and Managing Director, New York Center for Economic Transformation
7:30-8:30 p.m. Networking

To register, please click here.

If you have questions about this briefing, please contact
Kiirsten Lederer at (212) 351-4668 or

Event Detail

Morgan Stanley
Jump to Page

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.